Zacks Investment Research Upgrades Addus Homecare (NASDAQ:ADUS) to Hold

Zacks Investment Research upgraded shares of Addus Homecare (NASDAQ:ADUS) from a strong sell rating to a hold rating in a report published on Tuesday, January 9th.

According to Zacks, “ADDUS HOMECARE is a comprehensive provider of a broad range of social and medical services in the home. The company’s services include personal care and assistance with activities of daily living, skilled nursing and rehabilitative therapies, and adult day care. Its consumers are individuals with special needs who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. Its payor clients include federal, state and local governmental agencies, the Veterans Health Administration, commercial insurers and private individuals. Addus operates its business through two divisions, home & community services and home health services. The home & community services are social, or non-medical, in nature and include assistance with bathing, grooming, dressing, personal hygiene and medication reminders, and other activities of daily living whereas the home health services are medical in nature and include physical, occupational and speech therapy, as well as skilled nursing. “

Several other research firms also recently issued reports on ADUS. Oppenheimer reaffirmed a buy rating and set a $45.00 price objective on shares of Addus Homecare in a report on Tuesday, September 19th. BidaskClub raised shares of Addus Homecare from a sell rating to a hold rating in a report on Friday, January 5th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus target price of $41.33.

Addus Homecare (ADUS) traded down $0.50 during trading on Tuesday, reaching $36.50. 41,579 shares of the company’s stock traded hands, compared to its average volume of 24,081. The firm has a market cap of $424.57, a price-to-earnings ratio of 23.55, a PEG ratio of 1.61 and a beta of 0.06. The company has a current ratio of 2.68, a quick ratio of 2.68 and a debt-to-equity ratio of 0.23. Addus Homecare has a 1 year low of $29.90 and a 1 year high of $40.75.

Addus Homecare (NASDAQ:ADUS) last released its quarterly earnings data on Monday, November 6th. The company reported $0.42 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.38 by $0.04. Addus Homecare had a net margin of 4.30% and a return on equity of 10.35%. The firm had revenue of $108.60 million for the quarter, compared to analyst estimates of $108.99 million. During the same quarter in the prior year, the business earned $0.39 EPS. The company’s revenue for the quarter was up 4.9% compared to the same quarter last year. research analysts expect that Addus Homecare will post 1.42 EPS for the current fiscal year.

In other Addus Homecare news, CEO R Dirk Allison sold 749 shares of the firm’s stock in a transaction dated Monday, January 22nd. The shares were sold at an average price of $38.85, for a total value of $29,098.65. Following the completion of the sale, the chief executive officer now owns 33,120 shares in the company, valued at approximately $1,286,712. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider W Bradley Bickham sold 822 shares of the firm’s stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $37.40, for a total transaction of $30,742.80. Following the completion of the sale, the insider now owns 9,178 shares of the company’s stock, valued at approximately $343,257.20. The disclosure for this sale can be found here. 35.80% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of ADUS. Nordea Investment Management AB bought a new position in shares of Addus Homecare in the 2nd quarter valued at about $201,000. First Trust Advisors LP bought a new position in Addus Homecare during the 3rd quarter worth approximately $207,000. Eqis Capital Management Inc. bought a new position in Addus Homecare during the 3rd quarter worth approximately $218,000. The Manufacturers Life Insurance Company boosted its stake in Addus Homecare by 8.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 6,614 shares of the company’s stock worth $246,000 after acquiring an additional 517 shares during the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. bought a new position in Addus Homecare during the 2nd quarter worth approximately $264,000. 92.72% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Zacks Investment Research Upgrades Addus Homecare (NASDAQ:ADUS) to Hold” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/04/addus-homecare-adus-upgraded-to-hold-at-zacks-investment-research.html.

Addus Homecare Company Profile

Addus HomeCare Corporation is a provider of personal care services, which are provided primarily in the home. The Company’s personal care services include assistance with bathing, grooming, oral care, skincare, assistance with feeding and dressing, medication reminders, meal planning and preparation, housekeeping and transportation services and other activities of daily living.

Get a free copy of the Zacks research report on Addus Homecare (ADUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Addus Homecare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Addus Homecare and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply